Certara, Inc. reported the three-month period ended March 31, 2026 results: revenue $106.9 million, net income Net loss was $8.8 million, EPS Diluted loss per share of $0.06. Guidance lowered.
“First Quarter 2026 Results Total revenue for the first quarter of 2026 was $106.9 million, representing year-over-year growth of 1% on a reported basis. Software revenue for the first quarter of 2026 was $49.7 million, representing year-over-year growth of 7% on a reported basis. Services revenue for the first quarter of 2026 was $57.2 million, representing a year-over-year decrease of 4% on a reported basis . Total Bookings for the first quarter of 2026 were $115.3 million, representing a year-over-year decrease of 2%. Software Bookings for the first quarter of 2026 were $48.7 million, representing a year-over-year increase of 20%. The increase in software bookings was attributable to strong customer demand across our platform. Services Bookings for the first quarter of 2026 were $66.6 million, representing a year-over-year decrease of 14%. The decrease in services bookings was primarily driven by the timing of contract recognition and execution. Total cost of revenues for the first q”
Material Agreements
Certara, Inc. entered into Purchase Agreement with Veristat, LLC and certain of its affiliates valued at $100 million (effective 2026-04-21).
“On April 21, 2026, Certara, Inc. (the “Company”), together with certain of its subsidiaries, entered into a Purchase Agreement (the “Purchase Agreement”) with Veristat, LLC and certain of its affiliates (collectively, “Veristat”), pursuant to which the Company agreed to sell its global medical writing and related regulatory services business (the “Business”) to Veristat.”
Debt Financings
Certara, Inc. incurred term loan with Bank of America, N.A., as administrative agent for the Lenders and collateral agent for the secured parties thereunder at Term SOFR rate, with a floor of 0.00% plus an applicable margin rate of 2.75%.
“The Replacement Term Loans were funded in full on the Closing Date and were applied by the Company to refinance the Existing Term Loans (as defined in the Amendment) previously outstanding under the Credit Agreement.”
Debt Financings
Certara, Inc. amended credit facility with Bank of America, N.A., as administrative agent for the Lenders and collateral agent for the secured parties thereunder at Term SOFR rate, with a floor of 0.00% plus an applicable margin rate of 2.75%.
“The Amendment provides for, among other things, a reduction in the Applicable Rate (as defined in the Credit Agreement) with respect to the term loans under the Credit Agreement, which is expected to reduce the Company’s cost of borrowing and allow for interest expense savings, as compared to prior terms under the Credit Agreement.”
Dr. Patrick F. Smith departed as President, Certara Drug Development Solutions at Certara, Inc..
“On March 5, 2025, Certara, Inc. (the “Company”) announced that Dr. Patrick F. Smith, President, Certara Drug Development Solutions, stepped down from that role as of March 3, 2025, but will remain employed by the Company in a senior advisory and scientific role.”
Dr. John V. W. Reynders was appointed as Class II director at Certara, Inc..
“On October 16, 2024, the Board of Directors (the “Board”) of Certara, Inc. (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, voted to appoint Dr. John V. W. Reynders as a Class II director of the Board and a member of the Audit Committee of the Board, effective immediately.”
Earnings Releases
Certara, Inc. reported the first quarter of fiscal year 2024 results: revenue $96.7 million, net income Net loss was $4.7 million. Guidance reaffirmed.
“Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its financial results for the first quarter of fiscal year 2024. First Quarter Highlights: • Revenue was $96.7 million, compared to $90.3 million in the first quarter of 2023, representing growth of 7%. • Software revenue was $39.3 million , compared to $33.0 million in the first quarter of 2023”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.